Pinder S - Search Results

1

Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.

Gracio F, Burford B, Gazinska P, Mera A, Mohd Noor A, Marra P, Gillett C, Grigoriadis A, Pinder S, Tutt A, de Rinaldis E. Gracio F, et al. Among authors: pinder s. Sci Rep. 2017 Jan 6;7:40177. doi: 10.1038/srep40177. Sci Rep. 2017. PMID: 28059167 Free PMC article.

2

Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers.

Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM. Julien S, et al. Among authors: pinder se. Cancer Res. 2011 Dec 15;71(24):7683-93. doi: 10.1158/0008-5472.CAN-11-1139. Epub 2011 Oct 24. Cancer Res. 2011. PMID: 22025563 Free PMC article.

3

Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study.

Mantle PG, Dobrota M, Gillett CE, Odell EW, Pinder SE. Mantle PG, et al. Toxins (Basel). 2010 Apr;2(4):552-71. doi: 10.3390/toxins2040552. Epub 2010 Mar 31. Toxins (Basel). 2010. PMID: 22069599 Free PMC article.

4

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.

Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N; TNT Trial TMG; BCSC (UK). Robertson L, et al. Br J Cancer. 2012 Mar 13;106(6):1234-8. doi: 10.1038/bjc.2012.31. Epub 2012 Feb 14. Br J Cancer. 2012. PMID: 22333603 Free PMC article.

5

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group; Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. Curtis C, et al. Among authors: pinder s. Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983. Nature. 2012. PMID: 22522925 Free PMC article.

6

The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example.

Pinder SE, Brown JP, Gillett C, Purdie CA, Speirs V, Thompson AM, Shaaban AM; Translational Subgroup of the NCRI Breast Clinical Studies Group. Pinder SE, et al. J Clin Pathol. 2013 Mar;66(3):169-77. doi: 10.1136/jclinpath-2012-201091. Epub 2012 Oct 19. J Clin Pathol. 2013. PMID: 23087330 Review.

7

Comparative immunohistochemical analysis of ochratoxin A tumourigenesis in rats and urinary tract carcinoma in humans; mechanistic significance of p-S6 ribosomal protein expression.

Gazinska P, Herman D, Gillett C, Pinder S, Mantle P. Gazinska P, et al. Among authors: pinder s. Toxins (Basel). 2012 Sep;4(9):643-62. doi: 10.3390/toxins4090643. Epub 2012 Sep 11. Toxins (Basel). 2012. PMID: 23105973 Free PMC article.

8

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE. Gazinska P, et al. Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8. Mod Pathol. 2013. PMID: 23392436 Free article.

9

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.

de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S, Tutt A. de Rinaldis E, et al. Among authors: pinder s. BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643. BMC Genomics. 2013. PMID: 24059244 Free PMC article.

10

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A. Irshad S, et al. Among authors: pinder se. Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12. Breast Cancer Res Treat. 2014. PMID: 24519386 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

452 results

Search Page